7 stories found
Telix Pharmaceuticals and Regeneron Pharmaceuticals have announced a strategic collaboration to co-develop novel radiopharmaceutical therapies, combining their expertise in oncology and drug development.
Wall Street analysts are reportedly bullish on Telix Pharmaceuticals (TLX), with the article detailing the reasons for this positive outlook.
Telix Pharmaceuticals reported a GAAP EPS of -$2.11, missing estimates by $2.14, with revenue of $803.8 million also falling short by $22.79 million.
Telix Pharmaceuticals saw its stock increase after its imaging agent for brain cancer received a review designation from the U.S. Food and Drug Administration (FDA).
Telix Pharmaceuticals Limited held its Q4 2025 earnings call, summarizing its financial performance.
Telix Pharmaceuticals announced its first-quarter financial results, confirming its previously stated outlook for fiscal year 2026.
Telix Pharmaceuticals' second-half earnings call highlights have been published, providing an overview of the company's financial results.